Novo Nordisk is trading higher as markets refocus on expanding U.S. access for obesity medicines, following reports that Medicaid and Medicare programs are preparing to test coverage for weight-loss drugs—an approach that could broaden the addressable market for GLP-1 therapies over time. The proposed timing cited for the experiment has been April 2026 for Medicaid and January 2027 for Medicare, supporting a near-term sentiment lift for demand visibility across the category. (investing.com)

Coverage expansion matters because reimbursement has been one of the largest practical constraints on obesity-drug uptake in the U.S., and broader payer support can increase prescription volumes and persistence. Novo also has a newer commercial lever with its once-daily oral version of Wegovy (oral semaglutide), which was approved in the U.S. in late 2025 and made available in early 2026, potentially widening the funnel of patients who prefer pills over injections. (cen.acs.org)

Investors have also been watching efforts that could steer patients away from compounded GLP-1 products and back toward branded therapies. Earlier in 2026, the FDA issued warning letters to telehealth firms over misleading claims tied to compounded GLP-1 offerings, an enforcement posture that has been associated with positive moves in branded GLP-1 makers. (investing.com)

Near-term attention remains on how quickly any coverage pilot translates into meaningful utilization, and whether it expands beyond an “experiment” into sustained policy. On the company side, Novo’s U.S. 340B distribution/claims-data policy changes that took effect April 1, 2026 continue to draw scrutiny from hospital groups and could remain a headline risk for sentiment even as demand expectations improve. (novonordisk-us.com)